Amphastar Pharmaceuticals, Inc.

Listed Company

AMPHCIK 0001297184NasdaqLarge AcceleratedPharmaceutical PreparationsFY ends Dec 31

Period

FY 2025

Revenue

$719.89M

Net Income

$98.09M

Total Assets

$1.63B

Equity

$788.80M

Shares Out

44.09M

Op. Cash Flow

$156.12M

AMPH$19.74−9.10% · past yearDBEQ Basic

Daily closing prices

Business

Amphastar Pharmaceuticals is a biopharmaceutical company developing, manufacturing, and commercializing generic and proprietary injectable, inhalation, and intranasal pharmaceutical products, plus active pharmaceutical ingredients. The company markets over 25 prescription products and one over-the-counter product, including BAQSIMI® glucagon nasal powder, Primatene MIST®, and generic versions of glucagon, epinephrine, and lidocaine. Operating segments include marketed products in injectable and inhalation categories, as well as development-stage generic, biosimilar, and proprietary product candidates targeting high-barrier-to-entry markets. Distribution occurs through specialty distributors, wholesalers, and group purchasing organizations serving hospitals, clinics, pharmacies, and healthcare facilities domestically and internationally.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues	720	732	644	499	438
Cost of revenues	364	358	293	250	238
Gross profit	356	374	351	249	200
Selling, distribution, and marketing	44	38	29	22	17
General and administrative	86	57	52	45	51
Research and development	86	74	74	75	61
Total operating expenses	216	168	154	141	130
Income from operations	140	205	197	107	70
Interest income	9	11	5	1	601,000
Interest expense	−25	−30	−27	−2	—
Other income (expenses), net	23,000	4	−4	9	15
Total non-operating income (expenses), net	−17	−16	−26	9	14
Income before income taxes	124	190	171	116	84
Income tax provision	26	30	32	23	21
Income before equity in losses of unconsolidated affiliate	98	160	140	93	64
Equity in losses of unconsolidated affiliates	—	−573,000	−2	−1	−208,000
Net income	98	160	138	91	62
Basic	2.1	3.29	2.85	1.88	1.3
Diluted	2.03	3.06	2.6	1.74	1.25
Basic (in shares)	47	48	48	49	48
Diluted (in Shares)	48	52	53	52	50

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	170	152	144	156	126
Restricted cash	200,000	200,000	200,000	200,000	200,000
Short-term investments	113	70	113	20	10
Restricted short-term investments	2	2	2	2	2
Accounts receivable, net	144	136	115	89	79
Inventories	177	154	106	104	93
Income tax refunds and deposits	17	2	526,000	171,000	126,000
Prepaid expenses and other assets	13	18	9	8	7
Total current assets	636	534	490	378	318
Property, plant, and equipment, net	311	297	283	238	244
Finance lease right-of-use assets	221,000	383,000	564,000	753,000	353,000
Operating lease right-of-use assets	43	47	32	26	27
Goodwill and intangible assets, net	566	591	613	37	39
Long-term investments	—	11	15	—	—
Other assets	31	26	26	21	17
Deferred tax assets	42	71	53	39	22
Total assets	1,629	1,577	1,513	742	672
Accounts payable and accrued liabilities	148	157	93	84	90
Income taxes payable	239,000	10	2	5	9
Current portion of long-term debt	2	234,000	436,000	3	2
Current portion of operating lease liabilities	8	7	4	3	3
Total current liabilities	158	174	225	95	104
Long-term reserve for income tax liabilities	6	7	6	7	7
Long-term debt, net of current portion and unamortized debt issuance costs	609	602	590	73	75
Long-term operating lease liabilities, net of current portion	38	42	30	24	25
Other long-term liabilities	30	21	23	15	16
Total liabilities	840	845	873	213	226
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding	—	—	—	—	—
Common stock: par value $0.0001; 300,000,000 shares authorized; 61,779,883 and 45,645,497 shares issued and outstanding, respectively, as of December 31, 2025 and 60,847,124 and 47,617,691 shares issued and outstanding, respectively, as of December 31, 2024	6,000	6,000	6,000	6,000	6,000
Additional paid-in capital	535	505	486	455	422
Retained earnings	667	569	409	272	180
Accumulated other comprehensive loss	−5	−9	−8	−9	−7
Treasury stock	−408	−333	−247	−190	−150
Total stockholders' equity	789	732	639	529	446
Total liabilities and stockholders' equity	1,629	1,577	1,513	742	672

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net income	98	160	138	—	—
Loss on disposal of assets	39,000	9,000	475,000	141,000	348,000
Impairment of long-lived assets	—	—	3	—	—
Loss (gain) on interest rate swaps and foreign currency transactions, net	2	−3	5	−2	27,000
Depreciation of property, plant, and equipment	32	28	25	24	22
Amortization of intangible assets	25	25	13	954,000	1
Operating lease right-of-use asset amortization	7	4	4	4	3
Amortization of discounts, premiums, and debt issuance costs	3	6	11	466,000	219,000
Share-based compensation expense	27	24	20	18	19
Changes in reserve for uncertain tax positions	−1	891,000	−1	694,000	2
Changes in deferred taxes, net	29	−18	−13	−16	2
Accounts receivable, net	−6	−22	−26	−10	−15
Inventories	−21	−49	−2	−12	1
Prepaid expenses and other assets	−4	−11	−3	−2	3
Income tax refunds, deposits, and payable, net	−25	7	−3	−5	8
Operating lease liabilities	−6	−4	−4	−3	−3
Accounts payable and accrued liabilities	−5	64	13	−736,000	4
Net cash provided by operating activities	156	213	184	89	98
BAQSIMI acquisition	—	−129	−506	—	—
Purchases and construction of property, plant, and equipment	−35	−41	−38	−24	−27
Purchase of intangible assets	−2	—	—	—	—
Purchase of investments	−119	−77	−145	−36	−17
Maturity of investments	90	126	39	28	19
Deposits and other assets	−4	−4	1	1	3
Net cash used in investing activities	−70	−125	−649	−33	−29
Proceeds from equity plans, net of withholding tax payments (shares)	3	—	11	16	16
Proceeds from equity plans, net of withholding tax payments (shares)	—	−5	—	—	—
Purchase of treasury stock	−76	−85	−58	−40	−29
Debt issuance costs	−687,000	−816,000	−25	−407,000	−2
Proceeds from borrowing under lines of credit	6	18	—	—	—
Proceeds from Issuance of long-term debt	—	—	845	—	70
Principal payments on long-term debt	−223,000	−8	−319	−2	−37
Net cash provided by (used in) financing activities	−67	−81	454	−26	−37
Effect of exchange rate changes on cash	210,000	−190,000	−282,000	−220,000	−223,000
Net increase (decrease) in cash, cash equivalents, and restricted cash	19	7	−12	30	32
Deferred payment for BAQSIMI acquisition	—	—	122	—	—
Capital expenditures included in accounts payable	8	6	4	5	9
Operating lease right-of-use assets in exchange for operating lease liabilities	3	19	11	2	11
Interest paid, net of capitalized interest	23	27	18	3	2
Income taxes paid	23	40	49	44	8

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Amphastar Pharmaceuticals, Inc.'s CIK number?

Amphastar Pharmaceuticals, Inc.'s SEC CIK number is 0001297184 (1297184). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Amphastar Pharmaceuticals, Inc.'s SEC filings?

All of Amphastar Pharmaceuticals, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Amphastar Pharmaceuticals, Inc. last report earnings?

Amphastar Pharmaceuticals, Inc. (AMPH) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001297184-26-000031). This is Amphastar Pharmaceuticals, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Amphastar Pharmaceuticals, Inc.'s most recent earnings 8-K?

Amphastar Pharmaceuticals, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001297184-26-000031. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Amphastar Pharmaceuticals, Inc.'s latest earnings 8-K →
Look up any company's CIK number →